Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine
Portfolio Pulse from Happy Mohamed
Pulmatrix, Inc. (NASDAQ:PULM) has submitted an investigational new drug (IND) application to the FDA for PUR3100, a drug under development to treat acute migraine. The drug uses Pulmatrix's proprietary dry powder delivery technology, iSPERSE™. The IND includes a Phase 2 clinical protocol to investigate the safety and preliminary efficacy of PUR3100 in patients with acute migraine. Phase 1 study data showed similar pharmacokinetics to intravenous DHE with fewer side effects.
July 11, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulmatrix's submission of an IND application to the FDA for a Phase 2 trial of PUR3100 could potentially lead to a new treatment for acute migraine. This could have a positive impact on the company's stock in the short term.
The submission of an IND application to the FDA is a significant step in the drug development process. If approved, it could lead to a new treatment option for acute migraine, a condition that affects approximately 40 million patients in the U.S. This could potentially increase Pulmatrix's market share and revenue, positively impacting its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100